New data demonstrate the potential of Canopy's Remote Therapeutic Monitoring (RTM) Platform to improve patient care by reducing serious infections in patients with hematologic malignancies, resulting in an estimated $977,695 in annual savings per 1,000 patients.
Canopy, the leader in Enterprise AI for oncology, today announced new findings that highlight how its RTM Platform strengthens outpatient care and reduces infection-related escalations in patients with hematological malignancies.
Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy was presented on Saturday, December 6, 2025, during an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Key findings show:- Early symptom detection among patients using ePRO: 70% of patients with an infection-related acute event and 77% of those with an outpatient antibiotic order self-reported symptoms in the preceding 30 days. Several symptoms appear more commonly reported within 15 days before acute care events or antibiotic orders, underscoring the opportunity for earlier intervention.
- Increased use of outpatient antibiotics: Patients using ePRO were 20% more likely to receive outpatient antibiotics, resulting in fewer emergency visits and hospitalizations.
- Decreased acute-care utilization: Patients using ePRO were 52% less likely to experience an infection-related hospitalization and 33% less likely to have an infection-related ED visit.
- Substantial cost savings: Reduced infection-related acute-care utilization was associated with $977,695 in estimated annual savings per 1,000 patients, based on national AHRQ benchmarks.¹
"What stands out in this study is how often patients with hematologic malignancies reported symptoms before an acute event. Those reports frequently preceded the need for infection-related outpatient antibiotics, suggesting that earlier symptom visibility may help clinicians address issues before they escalate into acute events and higher-cost care.”
—Benjamin Derman, MD, presenting author and Assistant Professor of Medicine at the University of Chicago Medicine
"These results reinforce the value of having greater insight into patients' symptoms when they are away from the clinic. The added visibility remote therapeutic monitoring provides will matter even more as novel therapies with unique toxicities and infection risks continue to expand, such as bispecific T-cell engagers and CAR T-cell therapies.”
—James Essell, MD, Medical Director of the Center for Cancer and Cellular Therapy at Oncology Hematology Care (OHC) and The Jewish Hospital, and Chair for Cellular Therapy at Sarah Cannon Research Institute
The results from this study add to the growing body of evidence presented at ASH featuring the Canopy RTM Platform, including findings from the 2024 Annual ASH Meeting:
- 37% reduction in treatment discontinuation at three months2 [ASH, 2024]
- Improved early detection of toxicities with bispecific antibody therapies3 [ASH, 2024]
Other previous studies demonstrating the potential impact of Canopy's platform on oncology patient experience in real-world settings have demonstrated:
- 22% reduction in ER visits/hospitalizations per 100 patient months4 [ASCO, 2022]
- 45% improvement in treatment persistence at three months5 [ASCO, 2022]
- 88% patient engagement sustained at six months6 [JCO, 2022]
- Potential to improve adherence and manage toxicities associated with oral anticancer medications7 [ASCO Quality, 2025]
Continued research will examine how AI can further enhance Remote Therapeutic Monitoring and support earlier clinical intervention.
About Canopy
Canopy is a leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers across more than 500 sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.
Media Contact:
Kaitlin Hemric
kaitlin@canopycare.us
Learn More
Interested in learning more? Contact our team using the button below.
1 Roemer M: Cancer-Related Hospitalizations for Adults, 2017 [Internet], in Healthcare Cost and Utilization Project (HCUP)
Statistical Briefs. Rockville (MD), Agency for Healthcare Research and Quality (US), 2017 [cited 2025 Oct 27]
2 Essell, J. H., Derman, B. A., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 8). Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. American Society of Hematology Annual Meeting
3 Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting
4 Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508
5 Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528
6 Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180
7 Sharma, S., Doshi, G., Shumway, N., Schaefer, E., Dave, N., Marcus, A., Dyson, B., Derman, B., Essell, J., Ascha, M., Calkins, G., Neiman, J., Kwiatkowsky, L., & Kolodziej, M. (2025). Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications (OAM). JCO Oncology Practice, 21(suppl 10), abstract 594. DOI: 10.1200/OP.2025.21.10_suppl.594